Research News

NHS consultant and trainee research awards

Monday, 16 October 2017 13:56

The National Institute for Health Research (NIHR) Clinical Research Network have announced the winners of the research awards run in partnership with the Royal College of Physicians. One of the winners is BSG Trainee member Mark Samaan, Gastroenterology Clinical Research Fellow, Guy's and St Thomas' NHS Foundation Trust. The awards recognise outstanding contributions of NHS consultants and trainees who are active in research. To view the full list of winners visit the NIHR website.

Lancet editorial: cancer and obesity

Monday, 16 October 2017 13:20

A report released by the US Centers for Disease Control and Prevention highlighted that cancers associated with overweight and obesity constitute 40% of cancers diagnosed in the USA. The report observes that obesity is no longer primarily of concern for prevention of cardiovascular disease and diabetes, but also for prevention of cancer. The rise in incidence of obesity-related cancers, in contrast to the downward trend of other cancers, establishes progress on obesity as an essential public health goal. This is especially important for women, with the discovery that disparities between sexes in the rates of cancers associated with obesity are especially stark. See The Lancet for the full editorial.

Video and blog updates from the CRN Executive team

Monday, 16 October 2017 11:30

To encourage engagement with the CRN's Executive and Senior Management team, following the monthly Executive meeting, there will be a short briefing (video and written formats) presented by a member of the Executive team. There will also be a fortnightly blog written by members of the Senior Management team to provide staff with an understanding of 'on the ground' activity within each other's directorates. These updates will be in CRN connect and can be found on the NIHR website.

The benefits of biosimilar trials in the NHS

Monday, 16 October 2017 10:47

A new campaign led by NIHR CRN's Business Development and Marketing team, "Focus on biosimilars", explores some of the key questions associated with unlocking the potential benefits of biosimilars in the NHS through clinical trials. Biologic drugs have revolutionised the treatment of many serious and chronic illnesses in the NHS including rheumatoid arthritis and Inflammatory Bowel Disease (IBD), but are expensive to develop. They are thus expensive for the NHS to purchase resulting in restricted access for patients. As the patent protection for a number of leading biologic drugs is about to expire, the race is on to develop less expensive similar versions of biologics known as biosimilars.

Biosimilars have the promise of a smaller price tag and may well hold the key to ensuring the sustainability of our globally renowned public healthcare system. They will further broaden access to cutting edge treatments by providing new treatment options for patients just below the current biologics prescribing threshold. The acceptance of biosimilars across the NHS in recent years has rapidly accelerated with the clinical evidence base of biosimilars growing and the realisation of their benefits and cost savings.

"Focus on biosimilars" explores some of the key questions associated with unlocking the potential benefits of biosimilars in the NHS. To explore the campaign visit the NIHR website.

Page 3 of 36